logo
Sign In
Last Update: December 12, 2025
Dosage & administrationPrescribing informationFind savingsPubMed™ news
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.
  • Vowst (Fecal Microbiota Spores, Live-Brpk)

    Check Drug InteractionsCheck known drug interactions.
    Check Drug Interactions
    Find savings

    Dosage & administration

    For oral administration only. (
    2 DOSAGE AND ADMINISTRATION

    For oral administration only.

    2.1 Prior to taking the first dose

    2.2 Dosing regimen

    )


    PrescriberAI is currently offline. Try again later.

    By using PrescriberAI, you agree to the AI Terms of Use.

    This AI tool offers medical information for informational purposes only and is not a substitute for professional medical judgment or advice. Physicians and healthcare professionals should exercise their expertise and discretion when interpreting and applying the provided information to specific clinical situations.

    Vowst prescribing information

    VOWST is indicated to prevent the recurrence of

    Clostridioides difficile
    infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI).

    For oral administration only. (
    2 DOSAGE AND ADMINISTRATION

    For oral administration only.

    • Prior to taking the first dose:
      • Complete antibacterial treatment for rCDI 2 to 4 days before initiating treatment with VOWST.
      • Drink 296 mL (10 oz) of magnesium citrate on the day before and at least 8 hours prior to taking the first dose of VOWST. In clinical studies, participants with impaired kidney function received polyethylene glycol electrolyte solution (250 mL GoLYTELY, not approved for this use).
    • The dosage of VOWST is 4 capsules taken orally once daily for 3 consecutive days.
    • Take each dose (4 capsules) on an empty stomach prior to the first meal of the day.
    2.1 Prior to taking the first dose
    • Complete antibacterial treatment for recurrent CDI 2 to 4 days before initiating treatment with VOWST.
    • Drink 296 mL (10 oz) magnesium citrate, on the day before and at least 8 hours prior to taking the
      first
      dose of VOWST. In clinical studies, participants with impaired kidney function received polyethylene glycol electrolyte solution (250 mL GoLYTELY, not approved for this use)
      [see Clinical Studies (14)].
    • Do not eat or drink, except for small amount of water, for at least 8 hours prior to taking the first dose.
    2.2 Dosing regimen
    • The dosage of VOWST is 4 capsules taken orally once daily for 3 consecutive days.
    • Take each dose (4 capsules) on an empty stomach prior to the first meal of the day.
    )

    • Prior to taking the first dose:
      • Complete antibacterial treatment for rCDI 2 to 4 days before initiating treatment with VOWST. (
        2.1 Prior to taking the first dose
        • Complete antibacterial treatment for recurrent CDI 2 to 4 days before initiating treatment with VOWST.
        • Drink 296 mL (10 oz) magnesium citrate, on the day before and at least 8 hours prior to taking the
          first
          dose of VOWST. In clinical studies, participants with impaired kidney function received polyethylene glycol electrolyte solution (250 mL GoLYTELY, not approved for this use)
          [see Clinical Studies (14)].
        • Do not eat or drink, except for small amount of water, for at least 8 hours prior to taking the first dose.
        )
      • Drink 296 mL (10 oz) of magnesium citrate on the day before and at least 8 hours prior to taking the first dose of VOWST. In clinical studies, participants with impaired kidney function received polyethylene glycol electrolyte solution (250 mL GoLYTELY, not approved for this use). (
        2.1 Prior to taking the first dose
        • Complete antibacterial treatment for recurrent CDI 2 to 4 days before initiating treatment with VOWST.
        • Drink 296 mL (10 oz) magnesium citrate, on the day before and at least 8 hours prior to taking the
          first
          dose of VOWST. In clinical studies, participants with impaired kidney function received polyethylene glycol electrolyte solution (250 mL GoLYTELY, not approved for this use)
          [see Clinical Studies (14)].
        • Do not eat or drink, except for small amount of water, for at least 8 hours prior to taking the first dose.
        )
    • The dosage of VOWST is 4 capsules taken orally once daily for 3 consecutive days. (
      2.2 Dosing regimen
      • The dosage of VOWST is 4 capsules taken orally once daily for 3 consecutive days.
      • Take each dose (4 capsules) on an empty stomach prior to the first meal of the day.
      )
    • Take each dose (4 capsules) on an empty stomach prior to the first meal of the day. (
      2.2 Dosing regimen
      • The dosage of VOWST is 4 capsules taken orally once daily for 3 consecutive days.
      • Take each dose (4 capsules) on an empty stomach prior to the first meal of the day.
      )

    Capsule. A single dose is 4 capsules.

    Risk Summary

    All pregnancies have a background risk of major birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

    There are no data on use of VOWST in pregnant individuals. Developmental toxicity studies in animals have not been conducted with VOWST.

    None

    .

    Because VOWST is manufactured from human fecal matter, it may carry a risk of transmitting infectious agents. Any infection suspected by a healthcare provider possibly to have been transmitted by this product should be reported by the healthcare provider to Aimmune Therapeutics, Inc. at 1-833-246-2566.

    We receive information directly from the FDA and PrescriberPoint is updated as frequently as changes are made available
    View more
    Report Adverse Event

    Vowst PubMed™ news